AVOS Life Sciences

AVOS Large Cap Pharma Performance Outlooks

Banner

Purchase Options and Features

Type of Purchase Type of Deliverable
Individual monthly LCPPO module Delivered as a global license* PDF
Annual subscription

11 reports, delivered on a monthly basis (with the exception of August) as a global license* PDF. Subscribers are additionally entitled to the following benefits:

  • Four hours of analyst time each month to be used for data requests (e.g., income statements, specific product forecasts)
  • Historical LCPPO reports (and underlying spreadsheets)
Custom data and analysis
  • Scenario and sensitivity modeling built around client-specified events, e.g., delay/speed launch, drop/add a product, compress/lengthen time to peak sales.
  • Strategic performance and ranking of leading companies within a therapeutic area (e.g., cancer)
  • Comparative analysis of the free cash flow (FCF) of companies in a peer group that you specify
  • Provision of the complete set of consensus data for a given period - cleaned and aligned for analysis and accounting purposes**
* Global license PDF may be shared across the global enterprise, including all affiliates and subsidiaries.
** Analysts do not use consistent language in terms of product names, so it is often difficult to ascertain what products are included in a forecast. For example, "Avandia" forecasts sometimes include Avandaryl, Avandamet, and Avandia, but sometimes may only include Avandia and Avandamet, and then Avandaryl is either not given or forecasted separately. AVOS uses the historical company reported revenues from the previous year to make sure we are capturing the forecasts correctly. Similarly for the income statement data, analysts often give several "EPS" numbers; AVOS uses the historical data to make sure we are capturing the correct one.